SG50401A1 - 2,9-Disubstituted purin-6-ones - Google Patents

2,9-Disubstituted purin-6-ones

Info

Publication number
SG50401A1
SG50401A1 SG1996000260A SG1996000260A SG50401A1 SG 50401 A1 SG50401 A1 SG 50401A1 SG 1996000260 A SG1996000260 A SG 1996000260A SG 1996000260 A SG1996000260 A SG 1996000260A SG 50401 A1 SG50401 A1 SG 50401A1
Authority
SG
Singapore
Prior art keywords
ones
disubstituted purin
purin
disubstituted
Prior art date
Application number
SG1996000260A
Other languages
English (en)
Inventor
Elisabeth Perzborn
Erwin Bischoff
Helmuth Schutz
Matthias Schramm
Ulrich Niewohner
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of SG50401A1 publication Critical patent/SG50401A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
SG1996000260A 1995-01-19 1996-01-17 2,9-Disubstituted purin-6-ones SG50401A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19501482A DE19501482A1 (de) 1995-01-19 1995-01-19 2,9-disubstituierte Purin-6-one

Publications (1)

Publication Number Publication Date
SG50401A1 true SG50401A1 (en) 1998-07-20

Family

ID=7751830

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996000260A SG50401A1 (en) 1995-01-19 1996-01-17 2,9-Disubstituted purin-6-ones

Country Status (31)

Country Link
US (1) US5861404A (pt)
EP (1) EP0722944A1 (pt)
JP (1) JPH08231545A (pt)
KR (1) KR960029334A (pt)
CN (1) CN1135485A (pt)
AR (1) AR002953A1 (pt)
AU (1) AU4097996A (pt)
BG (1) BG61728B1 (pt)
BR (1) BR9600147A (pt)
CA (1) CA2167353A1 (pt)
CO (1) CO4700523A1 (pt)
CZ (1) CZ16696A3 (pt)
DE (1) DE19501482A1 (pt)
EE (1) EE9600018A (pt)
FI (1) FI960225A (pt)
HR (1) HRP960007A2 (pt)
HU (1) HUP9600106A3 (pt)
IL (1) IL116769A (pt)
MA (1) MA23778A1 (pt)
NO (1) NO960223L (pt)
NZ (1) NZ280830A (pt)
PE (1) PE64996A1 (pt)
PL (1) PL312354A1 (pt)
SG (1) SG50401A1 (pt)
SK (1) SK8096A3 (pt)
SV (1) SV1996000006A (pt)
TN (2) TNSN96007A1 (pt)
TR (1) TR199600028A2 (pt)
TW (1) TW314519B (pt)
YU (1) YU1396A (pt)
ZA (1) ZA96398B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19529102A1 (de) * 1995-08-08 1997-02-13 Kummer Horst Dieter Verwendung von PDE-Inhibitoren bei der Behandlung von Harnblasenerkrankungen
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
USRE37234E1 (en) 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
NZ502752A (en) * 1997-07-15 2001-01-26 Japan Energy Corp Purine derivatives and their use in the treatment of nephritis
CN1130363C (zh) 1997-11-12 2003-12-10 三菱化学株式会社 嘌呤衍生物以及含有其作为有效成分的药物
DE69815554T2 (de) * 1998-01-05 2004-05-06 Eisai Co., Ltd. Purinderivate und antagonisten des adenosin-a2-rezeptors, welche zur vorsorge oder heilung von diabetes dienen
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
ATE254616T1 (de) 1999-05-11 2003-12-15 Mitsubishi Chem Corp Dihydrat eines purinderivates, medikamente die dieses als aktiven wirkstoff enthalten und zwischenprodukte zu dessen herstellung
GB9924020D0 (en) 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
AU2001284444B2 (en) * 2000-09-06 2006-05-25 Mitsubishi Tanabe Pharma Corporation Preparations for oral administration
DE60236850D1 (de) * 2001-02-15 2010-08-12 Mitsubishi Tanabe Pharma Corp Tabletten, die in der mundhöhle schnell zerfallen
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
CN102742513A (zh) * 2012-07-17 2012-10-24 南京熊猫机电制造有限公司 一种喂食栏装置
EP3157520B1 (en) 2014-06-23 2019-09-04 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
CN114072407A (zh) 2019-04-02 2022-02-18 阿里戈斯治疗公司 靶向prmt5的化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451478A (en) * 1982-03-12 1984-05-29 Newport Pharmaceuticals International, Inc. Imidazole compounds
IL76546A (en) * 1984-10-12 1988-12-30 Warner Lambert Co 9-(heteroarylalkyl)-6-purine(thi)one derivatives,their preparation and pharmaceutical compositions containing them
GB9213623D0 (en) * 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
HUP9600106A2 (en) 1997-05-28
BR9600147A (pt) 1998-01-06
NO960223D0 (no) 1996-01-18
NZ280830A (en) 1998-04-27
KR960029334A (ko) 1996-08-17
DE19501482A1 (de) 1996-07-25
TW314519B (pt) 1997-09-01
FI960225A0 (fi) 1996-01-17
PE64996A1 (es) 1997-03-09
TNSN96006A1 (fr) 2005-03-15
SV1996000006A (es) 1996-10-29
AU4097996A (en) 1996-07-25
IL116769A (en) 1998-12-06
BG100292A (bg) 1996-07-31
IL116769A0 (en) 1996-05-14
CA2167353A1 (en) 1996-07-20
JPH08231545A (ja) 1996-09-10
YU1396A (sh) 1999-03-04
TNSN96007A1 (fr) 2005-03-15
NO960223L (no) 1996-07-22
ZA96398B (en) 1996-08-28
AR002953A1 (es) 1998-05-27
BG61728B1 (bg) 1998-04-30
US5861404A (en) 1999-01-19
TR199600028A2 (tr) 1996-08-21
CO4700523A1 (es) 1998-12-29
PL312354A1 (en) 1996-07-22
EE9600018A (et) 1996-08-15
HRP960007A2 (en) 1998-02-28
FI960225A (fi) 1996-07-20
HUP9600106A3 (en) 1998-04-28
CN1135485A (zh) 1996-11-13
HU9600106D0 (en) 1996-03-28
SK8096A3 (en) 1996-08-07
CZ16696A3 (en) 1996-08-14
MA23778A1 (fr) 1996-10-01
EP0722944A1 (de) 1996-07-24

Similar Documents

Publication Publication Date Title
DE59403259D1 (en) Tetraaroxyperylen-3,4,9,10-tetracarbonsäurepolyimide
GR3033254T3 (en) 1 alpha, 26-dihydroxy-D-homo-vitamin D3
ZA96398B (en) 2,9-Disubstituted purin-6-ones
MX213417B (es) Fenilpiridazinonas.
ZA964468B (en) Triazolylmethyl-cyclopentanols.
ZA961955B (en) Indazolecarboxamides.
ZA95462B (en) Substitute 1,2,3,4-tetrahydro -5-nitro-pyrimidines
GR3030863T3 (en) 2',5'-oligoadenylate-2',3'-cyclophosphates
AU6123196A (en) N-aryl-1,2,4-triazolin-5-ones
DE69610844D1 (en) Hydroformylierungsverfahren.
ZA946569B (en) 1,5-Diphenyl-3-pyrazolylalkyl-N-hydroxydithiocarbamates
PL326837A1 (en) 25-hydroxy-16-ene-26, 27-bishomocholecarctiferoles
GB9622283D0 (en) 3,4,5-Trifluorophenyl 4- cyclohexylbenzoates
GB9507199D0 (en) Leaflets
DE69637797D1 (en) Ten)phenylazoresorcinolen
GB9513818D0 (en) 7,7-Disubstituted cephem-4-ketones
ZA948311B (en) 1,2-dihydro-2-oxo-pyridines
IL110556A0 (en) 7 alpha-amino-1, 1-dioxocephem l- valylamides
GB2303409A8 (en) Turbine
GB9523965D0 (en) Windmill
GB2300675B (en) Turbines
ZA968953B (en) 24-homo-26,27-hexafluoro-cholecalciferols
ZA947884B (en) 1,2-dihydro-2-oxo-3-methylsulfonylaminomethylpyridines
GB9523183D0 (en) Turbines
HK1016577A1 (en) 25-hydroxy-16-ene-26,27-bishomo-cholecalciferols